Evisa Gjini

10.2k total citations · 1 hit paper
33 papers, 1.7k citations indexed

About

Evisa Gjini is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Evisa Gjini has authored 33 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Oncology, 10 papers in Molecular Biology and 9 papers in Immunology. Recurrent topics in Evisa Gjini's work include Cancer Immunotherapy and Biomarkers (23 papers), Immunotherapy and Immune Responses (8 papers) and CAR-T cell therapy research (6 papers). Evisa Gjini is often cited by papers focused on Cancer Immunotherapy and Biomarkers (23 papers), Immunotherapy and Immune Responses (8 papers) and CAR-T cell therapy research (6 papers). Evisa Gjini collaborates with scholars based in United States, Netherlands and Singapore. Evisa Gjini's co-authors include Scott J. Rodig, F. Stephen Hodi, Stefan Schulte‐Merker, Daniel Gusenleitner, Anita Giobbie‐Hurder, Belinda Cancilla, Hartwig Wolburg, Josi Peterson-Maduro, Axel M. Küchler and Mikel Lipschitz and has published in prestigious journals such as Nature Genetics, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Evisa Gjini

32 papers receiving 1.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma

2018 408 citations Scott J. Rodig, Daniel Gusenleitner et al. Science Translational Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Evisa Gjini United States	14	1.2k	633	544	303	197	33	1.7k
Ching Ching Leow United States	18	723 0.6×	501 0.8×	887 1.6×	122 0.4×	128 0.6×	33	1.7k
Shilpa Keerthivasan United States	11	877 0.7×	624 1.0×	637 1.2×	66 0.2×	122 0.6×	14	1.5k
Lee B. Rivera United States	15	853 0.7×	499 0.8×	626 1.2×	86 0.3×	154 0.8×	22	1.6k
Eleni Maniati United Kingdom	19	750 0.6×	708 1.1×	580 1.1×	62 0.2×	93 0.5×	40	1.6k
Jan Böhm Finland	22	717 0.6×	205 0.3×	478 0.9×	361 1.2×	146 0.7×	70	1.4k
Swapna S. Vemula United States	12	1.1k 0.9×	354 0.6×	1.1k 2.1×	89 0.3×	72 0.4×	19	2.0k
Marianna B. Ruzinova United States	15	504 0.4×	225 0.4×	822 1.5×	154 0.5×	121 0.6×	36	1.4k
Kevin Wei United States	5	982 0.8×	850 1.3×	466 0.9×	52 0.2×	109 0.6×	6	1.7k
Abel Sánchez‐Aguilera Spain	21	646 0.5×	485 0.8×	1.0k 1.9×	508 1.7×	75 0.4×	31	2.2k
Kabir A. Khan United Kingdom	15	489 0.4×	320 0.5×	547 1.0×	116 0.4×	69 0.4×	21	1.2k

Countries citing papers authored by Evisa Gjini

Since Specialization

Citations

This map shows the geographic impact of Evisa Gjini's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Evisa Gjini with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Evisa Gjini more than expected).

Fields of papers citing papers by Evisa Gjini

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Evisa Gjini. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Evisa Gjini. The network helps show where Evisa Gjini may publish in the future.

Co-authorship network of co-authors of Evisa Gjini

This figure shows the co-authorship network connecting the top 25 collaborators of Evisa Gjini. A scholar is included among the top collaborators of Evisa Gjini based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Evisa Gjini. Evisa Gjini is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Joshi, Adarsh, et al.. (2024). Abstract A024: Genomic peroxisome proliferator-activated receptor gamma (PPARG) study: A sponsored testing program to identify patients harboring genetic alterations in advanced UC in support of the FX-909 Phase 1 study. Clinical Cancer Research. 30(10_Supplement). A024–A024. 1 indexed citations

Gjini, Evisa, Stefan Kirov, & Michaela Bowden. (2023). 537 PPARG amplification is associated with lack of response to anti-PD1 in muscle-invasive urothelial cancer. SHILAP Revista de lepidopterología. A611–A611.

Ott, Patrick A., Kathleen L. Pfaff, Evisa Gjini, et al.. (2021). Combining CTLA-4 and angiopoietin-2 blockade in patients with advanced melanoma: a phase I trial. Journal for ImmunoTherapy of Cancer. 9(11). e003318–e003318. 12 indexed citations

Boucher, Yves, Ashwin S. Kumar, Jessica M. Posada, et al.. (2021). Bevacizumab improves tumor infiltration of mature dendritic cells and effector T-cells in triple-negative breast cancer patients. npj Precision Oncology. 5(1). 62–62. 30 indexed citations

Font‐Tello, Alba, Nikolas Kesten, Yingtian Xie, et al.. (2020). FiTAc-seq: fixed-tissue ChIP-seq for H3K27ac profiling and super-enhancer analysis of FFPE tissues. Nature Protocols. 15(8). 2503–2518. 22 indexed citations

Gurjao, Carino, David Liu, Matan Hofree, et al.. (2019). Intrinsic Resistance to Immune Checkpoint Blockade in a Mismatch Repair–Deficient Colorectal Cancer. Cancer Immunology Research. 7(8). 1230–1236. 60 indexed citations

Nabel, Christopher S., Mariano Severgnini, Yin P. Hung, et al.. (2019). Anti-PD-1 Immunotherapy-Induced Flare of a Known Underlying Relapsing Vasculitis Mimicking Recurrent Cancer. The Oncologist. 24(8). 1013–1021. 11 indexed citations

Monjazeb, Arta M., Anita Giobbie‐Hurder, Ana Lako, et al.. (2019). Analysis of colorectal cancer patients treated on ETCTN 10021: A multicenter randomized trial of combined PD-L1 and CTLA-4 inhibition with targeted low-dose or hypofractionated radiation.. Journal of Clinical Oncology. 37(8_suppl). 49–49. 9 indexed citations

Miller, Brian C., Debattama R. Sen, Rose Al Abosy, et al.. (2019). Abstract 2701: Functionally specialized subsets of exhausted CD8+ T cells mediate tumor control and differentially respond to checkpoint blockade. Cancer Research. 79(13_Supplement). 2701–2701. 3 indexed citations

10.

Cader, Fathima Zumla, Ron C.J. Schackmann, Xihao Hu, et al.. (2018). Mass cytometry of Hodgkin lymphoma reveals a CD4+ regulatory T-cell–rich and exhausted T-effector microenvironment. Blood. 132(8). 825–836. 111 indexed citations

11.

Rodig, Scott J., Daniel Gusenleitner, Donald Jackson, et al.. (2018). MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma. Science Translational Medicine. 10(450). 408 indexed citations breakdown →

12.

Schoenfeld, Jonathan D., Evisa Gjini, Scott J. Rodig, et al.. (2018). Evaluating the PD-1 Axis and Immune Effector Cell Infiltration in Oropharyngeal Squamous Cell Carcinoma. International Journal of Radiation Oncology*Biology*Physics. 102(1). 137–145. 23 indexed citations

13.

Griffin, Gabriel K., Margaretha G.M. Roemer, Mikel Lipschitz, et al.. (2018). Integrated Genetic and Topological Analysis Reveals a Hodgkin-like Mechanism of Immune Escape in T-Cell/Histiocyte-Rich Large B-Cell Lymphoma. Blood. 132(Supplement 1). 1579–1579. 2 indexed citations

14.

Moreira, Raphael Brandão, Lana Hamieh, Evisa Gjini, et al.. (2017). Regression of multifocoal in transit melanoma metastases after palliative resection of dominant masses and 2 years after treatment with ipilimumab. Journal for ImmunoTherapy of Cancer. 5(1). 61–61. 2 indexed citations

15.

Akahane, Koshi, Zhaodong Li, Julia Etchin, et al.. (2017). Anti‐leukaemic activity of the TYK2 selective inhibitor NDI‐031301 in T‐cell acute lymphoblastic leukaemia. British Journal of Haematology. 177(2). 271–282. 28 indexed citations

16.

Rodig, Scott J., Daniel Gusenleitner, Donald Jackson, et al.. (2017). Association of distinct baseline tissue biomarkers with response to nivolumab (NIVO) and ipilimumab (IPI) in melanoma: CheckMate 064.. Journal of Clinical Oncology. 35(15_suppl). 9515–9515. 1 indexed citations

17.

Wu, Xinqi, Anita Giobbie‐Hurder, Xiaoyun Liao, et al.. (2016). Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy. Cancer Immunology Research. 5(1). 17–28. 123 indexed citations

18.

Sridharan, Vishwajith, Evisa Gjini, Xiaoyun Liao, et al.. (2016). Immune Profiling of Adenoid Cystic Carcinoma: PD-L2 Expression and Associations with Tumor-Infiltrating Lymphocytes. Cancer Immunology Research. 4(8). 679–687. 77 indexed citations

19.

Hermans, Karlien, Filip Claes, Wei Zheng, et al.. (2010). Role of synectin in lymphatic development in zebrafish and frogs. Blood. 116(17). 3356–3366. 36 indexed citations

20.

Küchler, Axel M., Evisa Gjini, Josi Peterson-Maduro, et al.. (2006). Development of the Zebrafish Lymphatic System Requires Vegfc Signaling. Current Biology. 16(12). 1244–1248. 206 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact